Videos

REVIEW UroToday

PSMAfore Trial TT

Search

PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi Details Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
Innovative Prostate Cancer Therapy Insights Unveiled in ESMO 2023 Meeting - Alan Bryce Details Alan Bryce discusses the PSMAfore and other trials with Zach Klaassen. The trial, focusing on lutetium treatment for metastatic castration-resistant prostate cancer (mCRPC) in a pre-chemotherapy setting, shows a significant radiographic progression-free survival (rPFS) benefit. Dr. Bryce highlights the importance of selecting appropriate patients through PSMA PET scans prior to initiating treatmen...
PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - Oliver Sartor Details Oliver Sartor joins Alicia Morgans are discussing the eagerly anticipated results from the PSMAfore study (NCT04689828), a phase three trial exploring PSMA-617 lutetium for taxane-naive patients with metastatic castrate-resistant prostate cancer (mCRPC). Notable findings from the study revealed significantly improved radiographic progression-free survival (rPFS) with PSMA-617 lutetium vs a change...
Exploring the Latest Advances in Advanced Prostate Cancer Treatment - Oliver Sartor Details Alicia Morgans and Oliver Sartor discuss the latest developments and changes in the advanced prostate cancer landscape. Dr. Sartor mentions that novel hormones are used as first-line treatment in most cases and that the controversy around treating first-line metastatic CRPC is no longer relevant. He believes the evolution is going to continue with the novel hormones going earlier in different sett...
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris Details Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. At the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial which examines the role of [177Lu]Lu-PSMA-617 in taxane-naïve patients with mCRPC. Dr. Morris reviews the radiographic progression-free survival (rPFS) data from the VISION trial and the complementary dat...